A photograph cannot authenticate a Pfizer/Hospira bacteriostatic-water vial. A useful review begins by matching the claimed market and package to an official record, then following the lot, expiry, closure, liquid, seller, and purchase trail. Canadian, U.S., historical, and repackaged labels can differ legitimately, which makes a copied visual checklist a poor substitute for provenance.
This guide focuses on the current 30 mL Canadian presentation carrying DIN 00038202 and the U.S. Hospira 0.9% presentation carrying vial NDC 0409-3977-01. Those identifiers establish that a presentation exists in an official record. They cannot authenticate the individual vial in front of you because real identifiers and familiar artwork can be copied.
The market and package define the comparison
Canada and the United States use different official identifiers. A Canadian bottle compared only with U.S. artwork may look suspicious for completely legitimate reasons, while an alternate U.S. NDC may belong to a named repackager whose DailyMed record traces back to Hospira.
| Claimed presentation | Official record to check |
|---|---|
| Canada, 30 mL | Health Canada lists Bacteriostatic Water for Injection USP as a marketed Pfizer Canada ULC product under DIN 00038202. Pfizer Hospital Canada's September 2025 catalogue gives local code 03977030, GTIN 18821353977004, and a package of 25 x 30 mL vials. |
| U.S. original Hospira, 30 mL | The individual semi-rigid plastic Fliptop vial is NDC 0409-3977-01; the 25-vial tray is NDC 0409-3977-03. The current presentation contains 9 mg/mL, or 0.9%, benzyl alcohol. |
| U.S. repackaged, 30 mL | An alternate NDC can be legitimate when a DailyMed record names the repackager and traces the package to source NDC 0409-3977. Current examples include HealthFirst NDC 51662-1473-1 and ProPharma Distribution NDC 84549-977-03. |
The product name and volume belong beside the number. NDC 0409-1966-12 has appeared online as an identifier for 30 mL Hospira bacteriostatic water, while DailyMed assigns it to a 25-vial tray of 10 mL Bacteriostatic Sodium Chloride. DailyMed also carries an archived 20 mL, 1.1% Hospira presentation in the 0409-1093 product family, reinforcing the need to match market, name, concentration, volume, and package together.
Legitimate labels change
Hospira's own artwork has changed over time. The official 2018 and 2024 DailyMed archive images differ in typography, internal label code, and lot-and-expiry placement, giving two genuine layouts that should not be collapsed into one visual rule.
Repackaging creates another documented source of variation. A coherent record should connect the repackager name, its NDC, the source Hospira NDC, and the described package. DailyMed currently lists several repackaged products tied to source NDC 0409-3977, so an unfamiliar number calls for a record lookup before a verdict.
Contradictions deserve investigation
Appearance becomes useful when it exposes a conflict with the claimed record. A Canadian 30 mL bottle with no valid eight-digit DIN, a DIN resolving to another product, an unexplained U.S. identifier, covered or inconsistent lot information, a disturbed closure, or liquid that is discoloured or visibly particulate gives the manufacturer or regulator something concrete to investigate.
Cap shade, cap embossing, typography, label alignment, fill line, bottle seam, price, a matrix-like mark, and smell are weak stand-alone signals. Some buyers insist that FLIP OFF embossing proves a fake, while other reports dispute the same feature. Our article explaining why cap colour is not a certificate of analysis covers the broader problem with treating commodity packaging as identity evidence.
Public reports from 2025 and 2026 repeatedly mention cap embossing, absent lot details, unusual bottle shapes, uneven fill, altered-looking labels, and products that did not match a listing photograph. The Telegram discussions we reviewed also contain claims of fakes "flooding the market," along with debates about copied labels, neck shape, cap colour, and marks on the silver crimp.
One exchange initially treated Canadian artwork as suspicious because it differed from the familiar U.S. version, then returned to the DIN as the more relevant Canadian check. This is precisely where market-specific records prevent a false alarm. Repetition across forums establishes that the concern is real, while the absence of manufacturer investigation or laboratory work leaves the pictured units unresolved.
Pfizer's identification guidance says laboratory testing is required to confirm authenticity with certainty and warns that the usual visual clues may be absent. Health Canada similarly notes that counterfeit prescription products can look identical to approved products. Photographs can document a conflict and support an investigation without becoming a definitive authentication test.
Our search of official Pfizer, FDA, and Health Canada sources through July 24, 2026 did not locate a product-specific counterfeit alert for Pfizer/Hospira bacteriostatic water. The official product-specific event that appears prominently is the 2019 recall of lot W20308 for potential lack of sterility assurance, which was a manufacturing recall rather than a counterfeit alert. A dated search finding records what was located; it cannot prove that no counterfeit has ever existed.
A useful evidence trail
For a Canadian concern, preserve clear photographs of every label panel, the lot and expiry, and close views of the cap, crimp, stopper, and seal. Keep the invoice or receipt, seller page, and correspondence. Health Canada's complaint process specifically requests product, source, transaction, lot, expiry, photograph, and receipt information because those records can support an investigation.
Pfizer Canada Medical Information can be reached at 1-800-463-6001 and Pfizer Canada Customer Service at 1-800-387-4974. Health product complaints can be directed to Health Canada's compliance directorate at 1-800-267-9675. A manufacturer may recognize a known lot conflict from its records even when a photograph alone cannot settle the question.
We purchase our current Pfizer Canada stock from a Canadian pharmacy and retain the receipts. The presentation matches Pfizer Canada ULC and DIN 00038202 in the official record, and we guarantee the authenticity of the Pfizer bacteriostatic water sold by Precision Synthetics Canada. That guarantee covers our own traceable stock; it does not authenticate another seller's vial from a photograph. Pfizer describes counterfeits from domestic brick-and-mortar pharmacies in developed countries such as Canada as very unlikely, and Health Canada directs buyers toward licensed pharmacies and eight-digit DIN checks. Our stock is listed on our Pfizer Bacteriostatic Water 30 mL product page.
Sources and context
- Canadian product records: Health Canada Drug Product Database and Pfizer Hospital Canada Product Catalogue.
- U.S. product records: current Hospira label and archive, Bacteriostatic Sodium Chloride record, and the DailyMed repackager search.
- Authentication limits and sourcing context: Pfizer's identification article, Pfizer counterfeiting guidance, and Health Canada counterfeit guidance.
- Contacts, reporting, and the dated recall distinction: Pfizer Canada contacts, Health Canada complaint guidance, and the FDA-posted 2019 Hospira recall.
- Community screenshots are included as field reports about buyer concerns. They do not represent manufacturer, regulator, or laboratory authentication of the pictured products.
Research-use notice: Precision Synthetics Canada products and documentation are provided strictly for lawful, non-clinical laboratory research purposes only. COAs and testing records are not medical documents, safety guarantees, sterility guarantees, therapeutic endorsements, dosing guidance, or approval for human or veterinary use.